...
首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES)
【24h】

Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES)

机译:通过基于包含靶向内部核糖体进入位点(IRES)的shRNA的固体脂质纳米颗粒的非病毒载体沉默丙型肝炎病毒复制

获取原文
获取原文并翻译 | 示例
           

摘要

Gene silencing mediated by RNAi has gained increasing interest as an alternative for the treatment of infectious diseases such as refractory hepatitis C virus (HCV) infection. In this work we have designed and evaluated a non-viral vector based on solid lipid nanoparticles (SLN) bearing hyaluronic acid, protamine and a short hairpin RNA (shRNA74) targeted to the Internal Ribosome Entry Site (IRES) of the HCV. The vector was able to inhibit the expression of the HCV IRES in Huh-7 cells, with the inhibition level dependent on the shRNA74 to SLN ratio and on the shRNA74 dose added to the culture cells. The nanocarrier was also able to inhibit the replication in human hepatoma cells supporting a subgenomic HCV replicon (Huh-7 NS3-3'). The vector was quickly and efficiently internalized by the cells, and endocytosis was the most productive uptake mechanism for silencing. Clathrin-mediated endocytosis and to a lesser extent caveolae/lipid raft-mediated endocytosis were identified as endocytic mechanisms involved in the cell uptake. Internalization via the CD44 receptor was also involved, although this entry route seems to be less productive for silencing than endocytosis. The vector did not induce either hemolysis or agglutination of red cells in vitro, which was indicative of good biocompatibility. In summary, we have shown for the first time the ability of a non-viral SLN-based vector to silence a HCV replicon. (C) 2016 Elsevier B.V. All rights reserved.
机译:作为治疗难治性丙型肝炎病毒(HCV)感染等传染病的替代方法,RNAi介导的基因沉默已引起越来越多的关注。在这项工作中,我们设计和评估了一种基于固体脂质纳米颗粒(SLN)的非病毒载体,该脂质纳米颗粒带有透明质酸,鱼精蛋白和针对HCV内部核糖体进入位点(IRES)的短发夹RNA(shRNA74)。该载体能够抑制Huh-7细胞中HCV IRES的表达,抑制水平取决于shRNA74与SLN之比以及加入培养细胞的shRNA74剂量。纳米载体还能够抑制支持亚基因组HCV复制子(Huh-7 NS3-3')的人肝癌细胞中的复制。载体被细胞快速有效地内在化,内吞作用是沉默最有效的摄取机制。网格蛋白介导的内吞作用和小范围的小窝/脂质筏介导的内吞作用被确定为参与细胞摄取的内吞机制。通过CD44受体的内在化也参与其中,尽管这种进入途径对沉默的作用似乎不如内吞作用。该载体在体外不诱导红细胞溶血或凝集,这表明良好的生物相容性。总而言之,我们首次展示了基于非SLN的非病毒载体沉默HCV复制子的能力。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号